• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Macular Edema Pipeline Review H2 2017

    Diabetic Macular Edema Pipeline Review H2 2017

    • Report Code ID: RW0001884127
    • Category Pharmaceuticals
    • No. of Pages 193
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Diabetic Macular Edema - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

    Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 18, 6, 1, 21 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

    Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Diabetic Macular Edema - Overview 8
    Diabetic Macular Edema - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Diabetic Macular Edema - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Diabetic Macular Edema - Companies Involved in Therapeutics Development 29
    Aciont Inc 29
    ActiveSite Pharmaceuticals Inc 29
    Acucela Inc 30
    Aerie Pharmaceuticals Inc 30
    Aerpio Therapeutics Inc 31
    Alcon Laboratories Inc 31
    Allergan Plc 32
    Ampio Pharmaceuticals Inc 32
    Araim Pharmaceuticals Inc 33
    Boehringer Ingelheim GmbH 33
    Cell Medica Ltd 34
    Chengdu Kanghong Pharmaceuticals Group Co Ltd 34
    Clearside BioMedical Inc 35
    Coherus BioSciences Inc 35
    EyeGate Pharmaceuticals Inc 36
    F. Hoffmann-La Roche Ltd 36
    Formycon AG 37
    Genmab A/S 37
    GlaxoSmithKline Plc 38
    Icon Bioscience Inc 38
    Kala Pharmaceuticals Inc 39
    Kalvista Pharmaceuticals Inc 39
    Kowa Company Ltd 40
    Lupin Ltd 40
    Mabion SA 41
    Ocular Therapeutix Inc 41
    Oculis ehf 42
    Ohr Pharmaceutical Inc 42
    Pfizer Inc 43
    pSivida Corp 43
    Regeneron Pharmaceuticals Inc 44
    SciFluor Life Sciences LLC 44
    Senju Pharmaceutical Co Ltd 45
    Stealth BioTherapeutics Inc 45
    ThromboGenics NV 46
    Verseon Corp 46
    Xbrane Biopharma AB 47
    Diabetic Macular Edema - Drug Profiles 48
    (aflibercept + nesvacumab) - Drug Profile 48
    abicipar pegol - Drug Profile 50
    ACU-6151 - Drug Profile 53
    ACX-107 - Drug Profile 54
    aflibercept biosimilar - Drug Profile 55
    aflibercept biosimilar - Drug Profile 56
    AKB-9778 - Drug Profile 57
    ALG-1001 - Drug Profile 62
    Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 66
    AR-13154 - Drug Profile 67
    ARP-1536 - Drug Profile 68
    ASPPDC-010 - Drug Profile 69
    BI-1026706 - Drug Profile 70
    Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 72
    brolucizumab - Drug Profile 73
    bromfenac sodium - Drug Profile 76
    cibinetide - Drug Profile 78
    conbercept - Drug Profile 81
    danazol - Drug Profile 83
    darapladib - Drug Profile 87
    dexamethasone acetate - Drug Profile 90
    dexamethasone acetate - Drug Profile 96
    dexamethasone dipropionate XR - Drug Profile 98
    difluprednate - Drug Profile 99
    Drug for Diabetic Macular Edema - Drug Profile 100
    EBI-031 - Drug Profile 101
    elamipretide - Drug Profile 102
    fluocinolone acetonide SR - Drug Profile 110
    HO-10 - Drug Profile 119
    HPV-19 - Drug Profile 120
    JDE-006 - Drug Profile 121
    KPI-285 - Drug Profile 122
    KVD-001 - Drug Profile 123
    LKA-651 - Drug Profile 125
    NM-108 - Drug Profile 126
    OCX-063 - Drug Profile 127
    OTX-TKI - Drug Profile 128
    PF-655 - Drug Profile 130
    Protein to Inhibit VEGF for Ophthalmology - Drug Profile 133
    ranibizumab biosimilar - Drug Profile 134
    ranibizumab biosimilar - Drug Profile 135
    ranibizumab biosimilar - Drug Profile 136
    ranibizumab biosimilar - Drug Profile 138
    ranibizumab biosimilar - Drug Profile 139
    RG-7716 - Drug Profile 140
    ripasudil - Drug Profile 142
    SF-0166 - Drug Profile 144
    Small Molecule for Diabetic Macular Edema - Drug Profile 146
    Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 147
    Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile 148
    squalamine lactate - Drug Profile 149
    teprotumumab - Drug Profile 157
    THR-149 - Drug Profile 160
    THR-317 - Drug Profile 161
    triamcinolone acetonide - Drug Profile 164
    triamcinolone acetonide - Drug Profile 165
    VA-999272 - Drug Profile 172
    Diabetic Macular Edema - Dormant Projects 173
    Diabetic Macular Edema - Discontinued Products 175
    Diabetic Macular Edema - Product Development Milestones 176
    Featured News & Press Releases 176
    Appendix 188
    Methodology 188
    Coverage 188
    Secondary Research 188
    Primary Research 188
    Expert Panel Validation 188
    Contact Us 188
    Disclaimer 189

    List of Tables

    Number of Products under Development for Diabetic Macular Edema, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2) , H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Companies, H2 2017 (Contd..2) , H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1) , H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1) , H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2017
    Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Acucela Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Alcon Laboratories Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2017
    Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2017
    Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H2 2017
    Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017
    Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2017
    Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    Diabetic Macular Edema - Pipeline by Formycon AG, H2 2017
    Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2017
    Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H2 2017
    Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H2 2017
    Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2017
    Diabetic Macular Edema - Pipeline by Mabion SA, H2 2017
    Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2017
    Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H2 2017
    Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2017
    Diabetic Macular Edema - Pipeline by pSivida Corp, H2 2017
    Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
    Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2017
    Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2017
    Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H2 2017
    Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2017
    Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2017
    Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2017
    Diabetic Macular Edema - Dormant Projects, H2 2017
    Diabetic Macular Edema - Dormant Projects, H2 2017 (Contd..1) , H2 2017
    Diabetic Macular Edema - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Diabetic Macular Edema, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Targets, H2 2017
    Number of Products by Stage and Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    Aciont Inc
    ActiveSite Pharmaceuticals Inc
    Acucela Inc
    Aerie Pharmaceuticals Inc
    Aerpio Therapeutics Inc
    Alcon Laboratories Inc
    Allergan Plc
    Ampio Pharmaceuticals Inc
    Araim Pharmaceuticals Inc
    Boehringer Ingelheim GmbH
    Cell Medica Ltd
    Chengdu Kanghong Pharmaceuticals Group Co Ltd
    Clearside BioMedical Inc
    Coherus BioSciences Inc
    EyeGate Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    Formycon AG
    Genmab A/S
    GlaxoSmithKline Plc
    Icon Bioscience Inc
    Kala Pharmaceuticals Inc
    Kalvista Pharmaceuticals Inc
    Kowa Company Ltd
    Lupin Ltd
    Mabion SA
    Ocular Therapeutix Inc
    Oculis ehf
    Ohr Pharmaceutical Inc
    Pfizer Inc
    pSivida Corp
    Regeneron Pharmaceuticals Inc
    SciFluor Life Sciences LLC
    Senju Pharmaceutical Co Ltd
    Stealth BioTherapeutics Inc
    ThromboGenics NV
    Verseon Corp
    Xbrane Biopharma AB

    Request for Sample

    Report Url http://www.reportsweb.com//diabetic-macular-edema-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diabetic-macular-edema-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diabetic-macular-edema-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments